Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)
Gene Therapy·MeSH: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
2 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| FT819 | FATE THERAPEUTICS INC (FATE) |
Phase 1(1)
| Drug | Company |
|---|---|
| FT819 | Filana Therapeutics Inc. (FLNA) |
Frequently asked questions
How many drugs are in development for Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)?
BioSniper tracks 2 drugs in development for Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV) across 2 companies.
How many clinical trials target Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)?
There are 1 clinical trial targeting Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV) tracked by BioSniper.
Deep-dive into Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis